Alpha Tau Medical Ltd (DRTS) Stock AnalysisDRTSStock AnalysisAlpha Tau Medical Ltd

Alpha Tau Medical Ltd is an Israel-based medical technology company engaged in the research, development, and commercialization of innovative cancer treatment technologies. The Company focuses on Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), a platform designed for the treatment of solid tumors through the localized delivery of alpha radiation within tumor tissue. Its technology utilizes radioactive radium-224 sources that release short-range alpha particles intended to damage and destroy cancer cells while limiting exposure to surrounding healthy tissue. The Company conducts activities related to product development, clinical studies, regulatory approval processes, and commercialization. Alpha Tau Medical Ltd serves the oncology sector and carries out its operations directly and through its subsidiary, Healthcare Capital Corp. It operates in the Healthcare sector (SURGICAL AND MEDICAL INSTRUMENTS AND APPARATUS industry).

Alpha Tau Medical Ltd (DRTS) is a good buy right now, trading at $14.64 with a strong year-to-date change of +203.11%. The RSI is at 56.24, indicating a healthy momentum. Analyst price targets suggest a potential upside of 9% to 16% based on recent upgrades, with H.C. Wainwright targeting $16 and Barclays at $17. The main risk is the negative EPS trend, with a reported EPS of -0.50, reflecting ongoing losses, but the dual listing and FDA approvals could drive future growth.